The Experts below are selected from a list of 69 Experts worldwide ranked by ideXlab platform
Tibor Zelles - One of the best experts on this subject based on the ideXlab platform.
-
role of sodium channel inhibition in neuroprotection effect of vinpocetine
Brain Research Bulletin, 2000Co-Authors: Peter Bonoczk, Balazs Gulyas, Vera Adamvizi, Andras Nemes, Karpati Egon, Bela Kiss, Margit Kapas, Csaba Szantay, Istvan Koncz, Tibor ZellesAbstract:Abstract Vinpocetine (ethyl apovincaminate) discovered during the late 1960s has successfully been used in the treatment of central nervous system disorders of cerebrovascular origin for decades. The increase in the regional cerebral blood flow in response to vinpocetine administration is well established and strengthened by new diagnostical techniques (transcranial Doppler, near infrared spectroscopy, positron emission tomography). The latest in vitro studies have revealed the effect of the compound on Ca2+/calmodulin dependent cyclic guanosine monophosphate-phosphodiesterase 1, voltage–operated Ca2+ channels, glutamate receptors and voltage dependent Na+-channels; the latest being especially relevant to the neuroprotective action of vinpocetine. The good brain penetration profile and heterogenous brain distribution pattern (mainly in the thalamus, basal ganglia and visual cortex) of labelled vinpocetin were demonstrated by positron emission tomography in primates and man. Multicentric, randomized, placebo-controlled clinical studies proved the efficacy of orally administered vinpocetin in patients with Organic Psychosyndrome. Recently positron emission tomography studies have proved that vinpocetine is able to redistribute regional cerebral blood flow and enhance glucose supply of brain tissue in ischemic post-stroke patients.
Ilona Kovač - One of the best experts on this subject based on the ideXlab platform.
-
number of hospitalization due to dementias and Organic Psychosyndrome at zadar general hospital psychiatric ward in the last 20 years
Medica Jadertina, 2008Co-Authors: Ante Gilic, Robert Perincic, Ilona KovačAbstract:Po Izvjescu Svjetske zdravstvene organizacije o stanju dusevnog zdravlja u svijetu iz 2001. godine, AB i ostale demencije imaju prevalenciju od 0,6% u opcoj populaciji. Zadarska županija ima 165.000 stanovnika i predvidivo je da po toj stopi ima oko 1000 pacijenata s AB i ostalim demencijama. Pratili smo kretanje hospitalizacija poradi AB, ostalih demencija i organskog psihosindroma na Psihijatrijskom odjelu Opce bolnice Zadar kroz 20 godina i podijelili to razdoblje u dva dijela: od 1986. do 1995. godine (5 godina prije rata i 5 godina rata), te od 1996. do 2005. (deset godina poslije rata). Nasli smo da je broj hospitalizacija poradi AB, ostalih demencija i organskog psihosindroma, kroz razdoblje 1986-1995. godine bio: Alzheimerova bolest – 2, ostale demencije – 40, organski psihosindrom – 89, dakle ukupno 131, dok je ukupan broj hospitalizacija na psihijatrijskom odjelu u Zadru bio je 4439. Kroz razdoblje 1996.2005. godine broj hospitalizacija poradi istih poremecaja bio je: Alzheimerova bolest – 54, ostale demencije – 156, organski psihosindrom -138, dakle ukupno 348 od ukupno 6071 hospitalizacija. Znaci, u prvom promatranom razdoblju 2,64% od ukupno hospitaliziranih pacijenata hospitalizirano je poradi AB, ostalih demencija i organskog psihosindroma, a u razdoblju 1996.-2005. godine 5,73% od ukupno hospitaliziranih pacijenata hospitalizirano je poradi M. Alzheimer, ostalih demencija ili organskog psihosindroma. Izracunom smo pokazali da je ta razlika i statisticki znacajna. Te razlike možemo tumaciti na razne nacine – porastom broja demencija i organskog psihosindroma i povecanjem broja hospitalizacija ili pak smanjenjem tolerancije obitelji spram oboljelih od tih poremecaja i težnjom hospitalizaciji. U svakom slucaju drustvo i psihijatrijska djelatnost nalaze se pred problemom pojacanog pritiska za hospitalizacijom pacijenata s demencijom ili organskim psihosindromom, i kao drustvo moramo poduzeti adekvatne mjere u rjesavanju tog sve prisutnijeg problema.
-
Number of hospitalization due to dementias and Organic Psychosyndrome at Zadar General Hospital Psychiatric Ward in the last 20 years
General hospital Zadar, 2008Co-Authors: Ante Gilić, Robert Perinčić, Ilona KovačAbstract:Po Izvješcu Svjetske zdravstvene organizacije o stanju duševnog zdravlja u svijetu iz 2001. godine, AB i ostale demencije imaju prevalenciju od 0,6% u opcoj populaciji. Zadarska županija ima 165.000 stanovnika i predvidivo je da po toj stopi ima oko 1000 pacijenata s AB i ostalim demencijama. Pratili smo kretanje hospitalizacija poradi AB, ostalih demencija i organskog psihosindroma na Psihijatrijskom odjelu Opce bolnice Zadar kroz 20 godina i podijelili to razdoblje u dva dijela: od 1986. do 1995. godine (5 godina prije rata i 5 godina rata), te od 1996. do 2005. (deset godina poslije rata). Našli smo da je broj hospitalizacija poradi AB, ostalih demencija i organskog psihosindroma, kroz razdoblje 1986-1995. godine bio: Alzheimerova bolest – 2, ostale demencije – 40, organski psihosindrom – 89, dakle ukupno 131, dok je ukupan broj hospitalizacija na psihijatrijskom odjelu u Zadru bio je 4439. Kroz razdoblje 1996.- 2005. godine broj hospitalizacija poradi istih poremecaja bio je: Alzheimerova bolest – 54, ostale demencije – 156, organski psihosindrom -138, dakle ukupno 348 od ukupno 6071 hospitalizacija. Znaci, u prvom promatranom razdoblju 2,64% od ukupno hospitaliziranih pacijenata hospitalizirano je poradi AB, ostalih demencija i organskog psihosindroma, a u razdoblju 1996.-2005. godine 5,73% od ukupno hospitaliziranih pacijenata hospitalizirano je poradi M. Alzheimer, ostalih demencija ili organskog psihosindroma. Izracunom smo pokazali da je ta razlika i statisticki znacajna. Te razlike možemo tumaciti na razne nacine – porastom broja demencija i organskog psihosindroma i povecanjem broja hospitalizacija ili pak smanjenjem tolerancije obitelji spram oboljelih od tih poremecaja i težnjom hospitalizaciji. U svakom slucaju društvo i psihijatrijska djelatnost nalaze se pred problemom pojacanog pritiska za hospitalizacijom pacijenata s demencijom ili organskim psihosindromom, i kao društvo moramo poduzeti adekvatne mjere u rješavanju tog sve prisutnijeg problema.According to the World Health Organization report on the state of mental health published in 2001, the prevalence of AD and other dementias was 0.6% in the general population. Zadar county has 165.000 inhabitants, so, using this percentage, we can predict there are some 1000 patients with AD and dementia in our county. We have investigated the rate of hospitalization of patients with AD, other dementias and Organic Psychosyndrome in Zadar General Hospital Psychiatric Ward in the last 20 years. We divided this period into two parts – 1986 to 1995 (5 years before the war and 5 years of war) and 1996-2005 (ten years after the war). We found that the number of hospitalized patients with AD, other dementias and Organic Psychosyndrome in 1986-1995 was: Alzheimer\u27s disease – 2, other dementias – 40, Organic Psychosyndrome – 89, total – 131, and the total number of hospitalized patients was 4439. In the period of 1996-2005 the number of hospitalized patients with the same disorders was: Alzheimer`s disease – 54, other dementias – 156, Organic Psychosyndrome – 138, total – 348, and the total number of hospitalized patients was 6071. We can see that in the first monitored period 2.64% of hospitalized patients had AD, other dementias and Organic Psychosyndrome, and in the second period 5.73% of the hospitalized patients had these disorders. The difference is statistically significant. This difference can be interpreted in different ways – growth in the number of dementias and Organic Psychosyndrome patients and the increased number of hospitalizations or the decrease of family tolerance towards such patients and the wish for hospitalization. In any case, society and psychiatric professionals are confronting a problem of increased pressure in hospitalizing patients with dementia or Organic Psychosyndrome, and as a society we have to take adequate measures in solving this emerging problem
Peter Bonoczk - One of the best experts on this subject based on the ideXlab platform.
-
role of sodium channel inhibition in neuroprotection effect of vinpocetine
Brain Research Bulletin, 2000Co-Authors: Peter Bonoczk, Balazs Gulyas, Vera Adamvizi, Andras Nemes, Karpati Egon, Bela Kiss, Margit Kapas, Csaba Szantay, Istvan Koncz, Tibor ZellesAbstract:Abstract Vinpocetine (ethyl apovincaminate) discovered during the late 1960s has successfully been used in the treatment of central nervous system disorders of cerebrovascular origin for decades. The increase in the regional cerebral blood flow in response to vinpocetine administration is well established and strengthened by new diagnostical techniques (transcranial Doppler, near infrared spectroscopy, positron emission tomography). The latest in vitro studies have revealed the effect of the compound on Ca2+/calmodulin dependent cyclic guanosine monophosphate-phosphodiesterase 1, voltage–operated Ca2+ channels, glutamate receptors and voltage dependent Na+-channels; the latest being especially relevant to the neuroprotective action of vinpocetine. The good brain penetration profile and heterogenous brain distribution pattern (mainly in the thalamus, basal ganglia and visual cortex) of labelled vinpocetin were demonstrated by positron emission tomography in primates and man. Multicentric, randomized, placebo-controlled clinical studies proved the efficacy of orally administered vinpocetin in patients with Organic Psychosyndrome. Recently positron emission tomography studies have proved that vinpocetine is able to redistribute regional cerebral blood flow and enhance glucose supply of brain tissue in ischemic post-stroke patients.
I Chaviaras - One of the best experts on this subject based on the ideXlab platform.
-
study of the sensitivity of the Organic Psychosyndrome after one year of the disease
European Psychiatry, 2017Co-Authors: K Paschalidis, P Argitis, K Gatsiou, C Chatzidai, P P Dalli, E Pantoulas, I ChaviarasAbstract:Introduction The delirium of the elderly is defined as an acute confusional state, with variation during the day, characterized by impaired consciousness, orientation, memory, thinking, attention and behavior. Purpose The purpose of this research is to investigate whether the Organic Psychosyndrome of the elderly is a valid indicator of mortality after one year. Material It was used material from patients with Organic Psychosyndrome older than 60 years, who were hospitalized in pathological clinics of the Hospital of Corfu and was diagnosed by the linker portion of the psychiatric clinic. Methodology The patients diagnosed with Organic Psychosyndrome neither suffered from a psychiatric disorder psychotic type in the past, nor previously preceded anaesthesia in the context of physical disease. For the recognition and the criteria of ICD-10 to the exclusion of another psychiatric condition, it was used the delirium rating scale method. Results According to the analysis of the data, 8% of patients died during hospitalisation, in the first 3 months after diagnosis, the 28% of the initially hospitalised patients, in 6 months the 42%, while during the year the 48% of the initial total patients died and in the next 12 months only one death was reported. Conclusions The analysis of the survey results shows that while the instrument Psychosyndrome could be considered as a poor diagnostic marker for the first 12 months, 48% mortality, in the long run it seems to lose its prognostic value with the mortality approaching the mortality index of the hellenic statistical authority for 2015 at ages 60+ (1.2%).
Karpati Egon - One of the best experts on this subject based on the ideXlab platform.
-
role of sodium channel inhibition in neuroprotection effect of vinpocetine
Brain Research Bulletin, 2000Co-Authors: Peter Bonoczk, Balazs Gulyas, Vera Adamvizi, Andras Nemes, Karpati Egon, Bela Kiss, Margit Kapas, Csaba Szantay, Istvan Koncz, Tibor ZellesAbstract:Abstract Vinpocetine (ethyl apovincaminate) discovered during the late 1960s has successfully been used in the treatment of central nervous system disorders of cerebrovascular origin for decades. The increase in the regional cerebral blood flow in response to vinpocetine administration is well established and strengthened by new diagnostical techniques (transcranial Doppler, near infrared spectroscopy, positron emission tomography). The latest in vitro studies have revealed the effect of the compound on Ca2+/calmodulin dependent cyclic guanosine monophosphate-phosphodiesterase 1, voltage–operated Ca2+ channels, glutamate receptors and voltage dependent Na+-channels; the latest being especially relevant to the neuroprotective action of vinpocetine. The good brain penetration profile and heterogenous brain distribution pattern (mainly in the thalamus, basal ganglia and visual cortex) of labelled vinpocetin were demonstrated by positron emission tomography in primates and man. Multicentric, randomized, placebo-controlled clinical studies proved the efficacy of orally administered vinpocetin in patients with Organic Psychosyndrome. Recently positron emission tomography studies have proved that vinpocetine is able to redistribute regional cerebral blood flow and enhance glucose supply of brain tissue in ischemic post-stroke patients.